Statistics from Altmetric.com
Congenital adrenal hyperplasia (CAH) has an incidence of 1:14 000 to 1:18 000 worldwide. It is caused by autosomal recessive gene mutations, encoding enzymes in the adrenal steroidogenesis pathway. The majority, CYP21A1 mutations, result in 21-hydroxylase deficiency, with: inability to synthesise cortisol and aldosterone; diversion of increased steroid precursors, including 17-hydroxyprogesterone (17-OHP), into androgen production (figure 1). Neonates typically present with virilisation at birth, or in shock, ‘salt-losing crisis’, around days 10–14 of life. Some children present later with simple virilising CAH, often with milder compound heterozygous mutations.
Information about the guideline
This guideline focusses solely on CAH caused by 21-hydroxylase deficiency. It is written by the US Endocrine Society (2018) and cosponsored by several other organisations, including the European Society for Paediatric Endocrinology (ESPE). The guideline updates previous 2010 recommendations (box 1), particularly focussing on: if and when genital surgery should happen; prenatal treatment; ‘sick day’ rules; mental health and other comorbidities. The article spans from pregnancy to adulthood, but only paediatric guidance is summarised here.
Links to guideline and other resources
Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline.
20181 : https://academic.oup.com/jcem/article/103/11/4043/5107759
20102 : https://academic.oup.com/jcem/article/95/9/4133/2835216
Other useful resources
Patient/family support group: www.livingwithcah.com
Parent information sheet (UK): https:www.bsped.org.uk/media/1559/congenital-adrenal-hyperplasia-nov-18.pdf
Video (UK): how to give emergency intramuscular hydrocortisone https://m.youtube.com/watch?v=z4av7h5RH_o
Key issues addressed
Newborn screening, measuring blood spot 17-OHP
Standard practice in the USA and many other countries (although not in the UK), aiming to reduce morbidity and mortality, particularly for male babies, who unlike those with XX karyotype will not show virilisation at birth.
First-line testing using immunoassay has high sensitivity but many false positives. Second-line testing should use liquid chromatography-tandem mass spectrometry, with greater specificity and sensitivity.
Reference ranges for 17-OHP should …
Funding The author has not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.